Stanislas Pol

TL;DR: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.

TL;DR: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy.

TL;DR: In this article, the safety and efficacy of the combination of peginterferon alfa-2b and ribavirin was evaluated in HCV-infected patients.

TL;DR: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.

TL;DR: The intent of this study was to study a large group of patients to elucidate the following points: whether the pattern of distribution of HCV genotypes has been changing over time; whether severity of illness (chronic hepatitis, cirrhosis, and hepatocellular carcinoma) and response to interferon- therapy differs with theHCV genotype; and whether the level ofHCV viremia varies with severity of liver disease.